Anthony J. Olszanski

Fox Chase Cancer Center — United States

Medicine · Health Sciences

44h-index9.3kcitations421works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(138), Cancer Immunotherapy and Biomarkers(137), Cutaneous Melanoma Detection and Management(64), Radiopharmaceutical Chemistry and Applications(47), Melanoma and MAPK Pathways(45)

Publications420 total

Targeting chemoresistance: A phase II study of iadademstat (Iada) with paclitaxel (P) in extrapulmonary neuroendocrine carcinoma (epNEC) and small cell lung cancer (SCLC).
Journal of Clinical Oncology·2026
Supplementary Figure 2 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
2025Open Access
Supplementary Table 2 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
2025Open Access
Supplementary Table 1 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
2025Open Access
Supplementary figures and tables legends from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
2025Open Access
Supplementary Figure 1 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
2025Open Access
Supplementary Figure S1 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
2025Open Access
Supplementary Data 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
2025Open Access
Supplementary Table S2 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
2025Open Access
Supplementary Table S5 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
2025Open Access
Supplementary Table S4 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
2025Open Access
Supplementary Table 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
2025Open Access
Supplementary Table S3 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
2025Open Access
Supplementary Figures S1 to S7 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
2025Open Access
Supplementary Table S1 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
2025Open Access
Supplementary Methods 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
2025Open Access
Supplementary Figure 3 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Figure 8 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Figure 9 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Figure 1 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
page 1 of 21Next →

Frequent Co-authors

Thomas F. Gajewski(11), John A. Thompson(9), Dominick J. DiMaio(9), Julie R. Lange(9), Merrick I. Ross(9), Susan M. Swetter(9), Omid Hamid(9), Martin D. Fleming(8), Nicole R. McMillian(8), Yufan Zhao(8), Robert H.I. Andtbacka(7), F. Stephen Hodi(7), Sandip Pravin Patel(7), Jeffrey A. Sosman(7), Daniel G. Coit(7), William E. Carson(7), Valerie Guild(7), April K.S. Salama(7), Tara C. Gangadhar(7), Anita M. Engh(6)